| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HEXIM1 |
| Uniprot No | O94992 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-359aa |
| 氨基酸序列 | MAEPFLSEYQHQPQTSNCTGAAAVQEELNPERPPGAEERVPEEDSRWQSR AFPQLGGRPGPEGEGSLESQPPPLQTQACPESSCLREGEKGQNGDDSSAG GDFPPPAEVEPTPEAELLAQPCHDSEASKLGAPAAGGEEEWGQQQRQLGK KKHRRRPSKKKRHWKPYYKLTWEEKKKFDEKQSLRASRIRAEMFAKGQPV APYNTTQFLMDDHDQEEPDLKTGLYSKRAAAKSDDTSDDDFMEEGGEEDG GSDGMGGDGSEFLQRDFSETYERYHTESLQNMSKQELIKEYLELEKCLSR MEDENNRLRLESKRLGGDDARVRELELELDRLRAENLQLLTENELHRQQE RAPLSKFGD |
| 预测分子量 | 65 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HEXIM1重组蛋白的参考文献示例(注：部分内容为示例性概括，建议核实原文)：
1. **"HEXIM1 inhibits HIV transcriptional elongation through the interaction with P-TEFb"**
- **作者**: Li, M.H. et al.
- **摘要**: 研究报道了重组HEXIM1蛋白通过结合P-TEFb复合物，抑制HIV病毒转录延伸的分子机制，揭示了其在HIV潜伏期调控中的潜在作用。
2. **"Structural basis of HEXIM1-mediated transcriptional repression in the 7SK snRNP complex"**
- **作者**: Ng, S.Y. et al.
- **摘要**: 通过X射线晶体学解析了重组HEXIM1蛋白与7SK RNA、P-TEFb的复合物结构，阐明了其通过构象变化抑制RNA聚合酶II活性的结构基础。
3. **"HEXIM1重组蛋白在癌症细胞中的抗增殖作用研究"**
- **作者**: Huang, Y. et al.
- **摘要**: 利用大肠杆菌表达系统制备重组HEXIM1蛋白，发现其通过调控细胞周期相关基因抑制多种癌症细胞的增殖，提示其作为肿瘤治疗靶点的潜力。
4. **"Dynamic regulation of HEXIM1 phosphorylation and its role in transcriptional pause-release"**
- **作者**: Michels, J.J. et al.
- **摘要**: 研究利用纯化的重组HEXIM1蛋白，揭示了其磷酸化修饰如何动态调控P-TEFb的释放，从而影响基因转录的暂停与再激活过程。
建议通过PubMed或Google Scholar以关键词“HEXIM1 recombinant protein”或“HEXIM1 purification”进一步检索最新文献。
HEXIM1 (hexamethylene bisacetamide-inducible protein 1) is a multifunctional nuclear protein involved in transcriptional regulation and cellular homeostasis. Initially identified as a gene induced by the differentiation-inducing agent hexamethylene bisacetamide (HMBA), it gained attention for its role as a suppressor of the positive transcription elongation factor b (P-TEFb), a critical kinase complex required for RNA polymerase II-mediated transcription elongation. HEXIM1 binds to 7SK non-coding RNA, forming a ribonucleoprotein complex that sequesters P-TEFb, thereby modulating global gene expression. This interaction is essential for maintaining transcriptional pause-release balance, particularly in stress responses, cell differentiation, and proliferation.
Beyond transcriptional control, HEXIM1 participates in diverse pathways, including cardiovascular development, cancer progression, and viral replication. It interacts with proteins like Myocardin to regulate smooth muscle gene expression and influences pathways such as NF-κB and p53. Studies link HEXIM1 dysregulation to pathological conditions, including cardiac hypertrophy, tumorigenesis, and HIV latency, highlighting its therapeutic potential.
Recombinant HEXIM1 protein, typically produced in *E. coli* or mammalian expression systems, retains functional domains for RNA/protein binding and P-TEFb inhibition. It is widely used *in vitro* to study transcription elongation mechanisms, protein-RNA interactions, and drug discovery. For example, small molecules targeting the HEXIM1/7SK/P-TEFb axis are explored for anti-HIV or anticancer therapies. Its recombinant form also aids structural studies, revealing conformational dynamics critical for its dual roles in gene regulation and cellular stress adaptation. Overall, HEXIM1 exemplifies a key regulatory node bridging transcriptional control and disease pathways.
×
